Endeavor BioMedicines Appoints Paul Frohna, M.D., Ph.D., as Chief Medical Officer
Endeavor BioMedicines , a clinical-stage company developing therapies for of fibrotic disease and oncology, today announced the appointment of Paul Frohna, M.D., Ph.D., as its Chief Medical Officer.
- Endeavor BioMedicines , a clinical-stage company developing therapies for of fibrotic disease and oncology, today announced the appointment of Paul Frohna, M.D., Ph.D., as its Chief Medical Officer.
- “We’re pleased to welcome Paul as our Chief Medical Officer, and we look forward to his leadership as we progress our pipeline of therapies for patients with fibrosis and cancer,” said John Hood, Ph.D., Co-Founder, CEO and Chairman, Endeavor BioMedicines.
- “It is a privilege to join Endeavor as the company enters its next stage of growth," said Dr. Frohna.
- He has successfully designed and initiated translational and clinical programs for biologics, small molecules and stem cells across multiple therapeutic areas.